This is the authors' abstract. We don't add key points for this paper.
vp administered by intratumoral injection once every 2 weeks. Combination of AdAPT-001 with a checkpoint inhibition is enrolling.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Conley et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: